Feb 29, 2024 / 02:30PM GMT
Patrick Bernard Donnelly - Citigroup Inc., Research Division - Senior Analyst
(technical difficulty)
thinking about both the R&DS piece and the TAS piece and then we can kind of dive in from there.
Questions and Answers:
Ronald E. Bruehlman - IQVIA Holdings Inc. - Executive VP & CFOSure. Well, you know that the TAS business went through a period of softening revenue last year. And Q4, I think, was our softest quarter of all. What we're looking for in the TAS business as we go into 2024 -- through 2024, it's kind of almost a mirror image in terms of growth from what we saw in 2023, which is to say 2023 started out strong and the growth rate trailed off as we saw pharma clients cut back on discretionary spending.
We see demand coming back, but gradually towards the back half of the year. So you had the downward trend last year in growth, and we expect the revenue to bounce back growth as we go through the year. And you might ask what gives us confidence in that and really -- and we get that question frequently, it's hard to call
Trustpilot
